Prochlorperazine was synthesized in 1949 and introduced for the prevention of PONV in the 1950s. Although relatively few controlled studies are available, it is likely that prochlorperazine is an effective antiemetic. Elimination half-life is approximately 6 h and oral bioavailability is poor (Table 21.6).
Extrapyramidal side-effects are similar in nature to those associated with metoclopramide but less frequent. Sedation is not usually a problem in doses used for PONV. Rare side-effects include cholestatic jaundice, skin sensitization and haematological abnormalities.
Was this article helpful?